- Home
- GNL vs MYGN Comparison
GNL vs MYGN Comparison
Compare GNL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNL | MYGN |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 625.5M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | GNL | MYGN |
|---|---|---|
| Price | $8.29 | $7.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $9.00 | ★ $11.82 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 9.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $751,333,000.00 | ★ $825,300,000.00 |
| Revenue This Year | N/A | $0.10 |
| Revenue Next Year | N/A | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.63 | 0.21 |
| 52 Week Low | $6.51 | $3.76 |
| 52 Week High | $8.40 | $15.47 |
Technical Indicators
Market Signals| Indicator | GNL | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 50.91 |
| Support Level | $8.20 | $7.15 |
| Resistance Level | $8.40 | $7.43 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 82.47 | 29.31 |
Price Performance
Historical ComparisonAbout GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.